Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MITI 2

Financiado

Gut Microbiota-Induced Tregs for Inflammatory-Bowel-Disease (IBD) Immunotherapy...

Gut Microbiota-Induced Tregs for Inflammatory-Bowel-Disease (IBD) Immunotherapy (MITI2) Our project focuses on the regulatory properties of a subset of microbiota-specific TR1-like regulatory T (Treg) cells, for which we have already shown an unprecedented association with the clinical outcome of patients in various... ver más

30/04/2027

INSERM

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 7 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-28

HORIZON-HLTH-2022-DISEASE-06-02-two-stage: Pre-clinical development of the nex... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 2 años

0% 100% 100%

7 Participantes

INSERM

4.31M€ | Lider

METATISSUE

328.57K€ | Participante

UNIVERSITY OF APPLIED SCIENC...

382.25K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2017-82290-R SISTEMAS MULTIFUNCIONALES BASADOS EN CELULAS MADRE MICROENCA... 157K€ Cerrado

EIN2020-112225 DESENTRAÑAR UN MECANISMO PARACRINO PARA LA HOMEOSTASIS INTES... 10K€ Cerrado

BFU2008-02683 NUEVOS MEDIADORES DE LA RESPUESTA T EFECTORA Y POTENCIAL TER... 121K€ Cerrado

MicroT Microbiota-T cell interactions - antigen-specificity and reg... 2M€ Cerrado

RTI2018-101586-A-I00 CONTROL PRECISO DE LA NATURALEZA DE LA AUTOFAGIA EN LA HOMEO... 157K€ Cerrado

RYC-2010-07051 Role of the intestinal microbiota in inflammatory bowel dise... Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2023-04-28
Fecha Fin: 2027-04-30

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Descripción del proyecto Our project focuses on the regulatory properties of a subset of microbiota-specific TR1-like regulatory T (Treg) cells, for which we have already shown an unprecedented association with the clinical outcome of patients in various inflammatory diseases, for a therapeutic use in inflammatory bowel diseases (IBD). IBD is a disabling chronic inflammatory process that affects young individuals and causes many life-altering symptoms, and represents a risk factor for colon cancer. Existing treatments are complex, with most people requiring lifelong medications as well as dietary and lifestyle modifications, and some requiring surgery. In this context, the development of new therapeutic approaches appears essential and immunotherapy and cell-based therapy are particularly promising strategies for this disease. Teams from Nantes have a strong expertise in the field of human immunology, mucosal immunology and immunotherapeutic strategies applied to various pathological conditions, including gut inflammatory diseases. They recently identified a novel microbiota-induced Treg subset, associated with good prognosis in IBD patients, thus representing a promising candidate for innovative immunotherapeutic approaches. Based on the limitation to develop immunotherapy approach for human diseases by using animal models due to immune system specificities/differences and ethical considerations, we opted for the development of an ex vivo human preclinical model that will reconstitute the physiological complexity of the human gut. Teams from Strasbourg have a strong experience and already set-up models of organoids in different pathological systems, that will perfectly fit to be used as ex vivo preclinical models for this project. This proposal aims thus at providing a pre-clinical package including i) the proof of concept that a cellular immunotherapy using the identified Tregs subset represents a treatment for IBDs and ii) the reglementary pre-clinical in vitro and in vivo toxicity.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores